核药是目前的热点,...查看全文
Cellectar(CLRB)02-15 04:25
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000935836-24-000191 Act: 34 Size: 30 KB 网页链接查看全文
Cellectar(CLRB)02-15 05:35
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023800 Act: 34 Size: 170 KB 网页链接查看全文
Cellectar(CLRB)02-15 05:55
$Cellectar(CLRB)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023902 Act: 34 Size: 52 KB 网页链接查看全文
Cellectar(CLRB)03-27 18:35
$Cellectar(CLRB)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001410578-24-000307 Act: 34 Size: 6 MB 网页链接查看全文
Cellectar(CLRB)03-27 18:55
$Cellectar(CLRB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-039341 Act: 34 Size: 277 KB 网页链接查看全文
Cellectar(CLRB)04-26 08:05
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001622627-24-000028 Act: 34 Size: 111 KB 网页链接查看全文
Cellectar(CLRB)04-27 05:05
$Cellectar(CLRB)$ ARS Annual Report to Security Holders Accession Number: 0001104659-24-053062 Act: 34 Size: 658 KB 网页链接查看全文
Cellectar(CLRB)02-15 09:35
$Cellectar(CLRB)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001622627-24-000007 Act: 34 Size: 109 KB 网页链接查看全文
Cellectar(CLRB)04-02 05:35
$Cellectar(CLRB)$ 10-K/A [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001104659-24-041930 Act: 34 Size: 408 KB 网页链接查看全文
美股滚雪球03-27 22:00
$Cellectar(CLRB)$ 今天发布了财报,此前发布的iopofosine I 131治疗Waldenstrom’s macroglobulinemia (WM)的三期数据不错,预计在下半年递交NDA,二季度也有研发更新;公司还有核药新型α -释放磷脂放射治疗偶联物CLR 121255,目前用于胰腺癌的治疗,尚处于临床前阶段。
核药是目前的热点,...查看全文
市场调研报告2022-12-16 16:56
据恒州诚思调研统计,2021年全球儿科肿瘤治疗市场规模约 亿元,2017-2021年年复合增长率CAGR约为 %,预计未来将持续保持平稳增长的态势,到2028年市场规模将接近 亿元,未来六年CAGR为 %。
本文调研和分析全球儿科肿瘤治疗发展现状及未来趋势,核心内容如下:
(1)全球市场总体规模,按收...查看全文
市场调研报告2022-12-16 16:54
本文调研和分析全球儿科肿瘤治疗发展现状及未来趋势,核心内容如下:
(1)全球市场儿科肿瘤治疗总体规模,按收入进行了统计分析,历史数据2017-2021年,预测数据2022至2028年。
(2)全球市场竞争格局,全球市场头部企业儿科肿瘤治疗市场占有率及排名,数据2017-2021年。
(3)中国市...查看全文
牛唐2020-12-24 11:26
医药板块速评(2020.12.23)
1、$Athenex(ATNX)$ 口服紫杉醇审批在即,可否参与投资?
2、$Cellectar(CLRB)小而美意外增发,可否迎来抄底良机?
3、$INmune Bio(INMB)阿尔海默兹药物数据发布在即,能否小赌怡情?
$香雪制药(SZ300147)$ $阿里巴巴-SW(09988)$查看全文
$CELLECTAR BIOSCIENCES INC(CLRB)$ 8-K - Current report Filed: 2016-09-12 AccNo: 0001144204-16-123591 Size: 28 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 8-K - Current report Filed: 2016-08-12 AccNo: 0001144204-16-118731 Size: 40 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-08-11 AccNo: 0001144204-16-118346 Size: 3 MB 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 美东时间 2016-08-15 09:00 Before Open:CELLECTAR BIOSC Earning Release . Wall St EPS Est ($):-0.40. 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 8-K - Current report Filed: 2016-08-09 AccNo: 0001144204-16-117671 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ EFFECT - Notice of Effectiveness Filed: 2016-07-27 AccNo: 9999999995-16-005251 Size: 1 KB 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 8-K - Current report Filed: 2016-07-27 AccNo: 0001144204-16-114706 Size: 12 KBItem 4.01: Changes in Registrant's Certifying Accountant 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ POS AM - Post-Effective amendments for registration statement Filed: 2016-07-26 AccNo: 0001144204-16-114486 Size: 438 KB 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-07-25 AccNo: 0001144204-16-114166 Size: 44 KB 网页链接
$CELLECTAR BIOSCIENCES INC(CLRB)$ 8-K - Current report Filed: 2016-07-20 AccNo: 0001144204-16-113716 Size: 34 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 7.0...